TOPS System
Premia Spine, Ltd. · Decision date Jun 15, 2023
What did the FDA approve?
FDA records P220002 as an original PMA application. The recorded decision is approval, dated Jun 15, 2023.
FDA approval order statement
Approval for The TOPS System is a motion-preserving spinal implant that is inserted into the lumbar spine via pedicle screws. The TOPS System is intended to stabilize the spine following a lumbar decompression without rigid fixation.The TOPS System is indicated for patients between 35 and 80 years of age with symptomatic degenerative spondylolisthesis up to Grade I, with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum and/or of the scarring facet joint capsule at one level from L3 to L5.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Jun 15, 2023
Regulatory record facts
- Identifier
- P220002
- Regulatory pathway
- Premarket approval application
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- Decision code
- APPR
- Decision date
- Jun 15, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, posterior spinal elements.
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220002 received
Application receipt date recorded by FDA.
P220002 · FDA decision
APPR
P220002/S011 · Related supplement
TOPS System
Timeline entries are records held by MedtechLedger for P220002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TOPS SystemP220002/S011 | Premia Spine, Ltd. | PMA supplement | Sep 9, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Premia Spine, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7 Giborey Israel St., Ramat Poleg, Netanya, 4250407
Sources and methodology
- Original FDA record: P220002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records